

Accepted Manuscript


Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma

Daisuke Kubota, Kenta Mukaiharu, Akihiko Yoshida, Hitoshi Tsuda, Akira Kawai, Tadashi Kondo

PII: S1874-3919(13)00414-4
DOI: doi: [10.1016/j.jprot.2013.07.022](https://doi.org/10.1016/j.jprot.2013.07.022)
Reference: JPROT 1517

To appear in: *Journal of Proteomics*

Received date: 27 March 2013
Accepted date: 24 July 2013



Please cite this article as: Kubota Daisuke, Mukaiharu Kenta, Yoshida Akihiko, Tsuda Hitoshi, Kawai Akira, Kondo Tadashi, Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma, *Journal of Proteomics* (2013), doi: [10.1016/j.jprot.2013.07.022](https://doi.org/10.1016/j.jprot.2013.07.022)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Peroxiredoxin 2 as a predictive biomarker for induction chemotherapy in osteosarcoma

Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma

Daisuke Kubota^{1,2}, Kenta Mukaiharu¹, Akihiko Yoshida³, Hitoshi Tsuda³, Akira Kawai⁴,
Tadashi Kondo¹

1. Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo,
Japan

2. Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo,
Japan

3. Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo,
Japan

4. Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo,
Japan

All correspondence:

Tadashi Kondo, MD, PhD

Division of Pharmacoproteomics, National Cancer Center Research Institute

5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Tel.: +81-3-3542-2511, Fax: +81-3-3547-5298

E-mail: takondo@ncc.go.jp

Running head: Peroxiredoxin 2 predicts osteosarcoma responsiveness to induction
chemotherapy

Download English Version:

<https://daneshyari.com/en/article/7637354>

Download Persian Version:

<https://daneshyari.com/article/7637354>

[Daneshyari.com](https://daneshyari.com)